PIK3CG and fragile X syndrome: First, some of the treatments already tested in mouse models of ASD have been able to ameliorate both cognitive and morphological alterations; moreover, a few clinical tests with humans show promising results (this is true at least for the use of mGluR5 regulators in FXS or PI3K activators for Rett syndrome treatment).